Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.

<h4>Purpose</h4>Pathological angiogenesis and vascular instability are observed in diabetic retinopathy (DR), diabetic macular edema (DME), and wet age-related macular degeneration (wAMD). Many receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptors (VEGFR...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Sophie J Bakri, Jeff Lynch, Michelle Howard-Sparks, Stephan Saint-Juste, Said Saim
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Online Access:	https://doi.org/10.1371/journal.pone.0304782

Similar Items

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
by: Francesca Lazzara, et al.
Published: (2024-06-01)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
by: Alexander Chehrazi-Raffle, et al.
Published: (2020-06-01)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
by: Jung Hyun Shin, et al.
Published: (2023-05-01)

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
by: Kathryn E. Beckermann, MD, PhD, et al.
Published: (2024-02-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
by: Eva Juengel, et al.
Published: (2021-11-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
by: Rebecca Wray, et al.
Published: (2025-04-01)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
by: Wen Cai, et al.
Published: (2019-10-01)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)

Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells
by: Reinhardt Krcek, et al.
Published: (2017-08-01)

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma
by: Kazuyuki Numakura, et al.
Published: (2024-12-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
by: Bernard Paule, et al.
Published: (2010-05-01)

Pro-Angiogenic Bioactive Molecules in Vascular Morphogenesis: Integrating Endothelial Cell Dynamics
by: Claudiu N. Lungu, et al.
Published: (2025-10-01)

Angiogenic properties and intercellular communication of differentiated porcine endothelial cells in vascular therapy
by: Bo-Gyeong Seo, et al.
Published: (2024-10-01)

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
by: Janet Brown, et al.
Published: (2024-01-01)

Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption
by: J.I. Aguirre, et al.
Published: (2025-06-01)

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101
by: M-O. Grimm, et al.
Published: (2022-08-01)

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
by: Brian Rini, et al.
Published: (2024-07-01)

Endothelial EphrinB2 Regulates Sunitinib Therapy Response in Murine Glioma
by: Thomas Broggini, et al.
Published: (2022-05-01)

Aerobic Training Improves Angiogenic Potential Independently of Vascular Endothelial Growth Factor Modifications in Postmenopausal Women
by: Pascal Izzicupo, et al.
Published: (2017-12-01)

Unexpected skin lesions after axitinib treatment
by: Ali Murat Sedef, et al.
Published: (2017-07-01)

Phase Separation Investigation of Axitinib in Supersaturated Solution
by: Jie Xu, et al.
Published: (2024-11-01)

Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation
by: Yinhu Pan, et al.
Published: (2024-10-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022-06-01)

Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells.
by: Elena Garonna, et al.
Published: (2011-04-01)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
by: Annkristin Heine, et al.
Published: (2015-01-01)

Role of angiogenic transdifferentiation in vascular recovery
by: John P. Cooke, et al.
Published: (2023-05-01)

Correction: Vascular Endothelial Growth Factor Receptor-2 Couples Cyclo-Oxygenase-2 with Pro-Angiogenic Actions of Leptin on Human Endothelial Cells.
by: Elena Garonna, et al.
Published: (2019-01-01)

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
by: Yoshifumi Kadono, et al.
Published: (2019-09-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
by: Ulkuhan I. Koksal, et al.
Published: (2020-01-01)

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
by: Monica Oldani, et al.
Published: (2024-07-01)

Variables Affecting the Preparation and Characterization of Axitinib as Oral Niosmoes
by: Ibtihal Abdulkadhim Dakhil, et al.
Published: (2024-09-01)

Acute sunitinib neurotoxicity
by: Ahmet GULMEZ, et al.
Published: (2021-01-01)

Role of autophagy in angiogenic potential of vascular pericytes
by: Soheil Zamen Milani, et al.
Published: (2024-02-01)

An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors.
by: Beverly L Falcon, et al.
Published: (2014-01-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)